Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12891317 | 1.00 | P2RX7 (1.00) | P2RX7P2RX3 | |
| Hydrochloric Acid SCHEMBL4507870 | 0.99 | P2RX7 (1.00) | P2RX7P2RX3 | |
| Hydrochloric Acid SCHEMBL31722657 | 0.99 | P2RX7 (1.00) | P2RX7P2RX3 | |
| SCHEMBL4507991 | 0.94 | P2RX7 (0.89) | P2RX7P2RX3 | |
| SCHEMBL4507297 | 0.93 | P2RX7 (0.86) | P2RX7P2RX3 | |
| SCHEMBL4498519 | 0.92 | P2RX7 (0.84) | P2RX7P2RX3 | |
| SCHEMBL4510913 | 0.91 | P2RX7 (0.83) | P2RX7P2RX3 | |
| SCHEMBL4513258 | 0.90 | P2RX7 (1.00) | P2RX7P2RX3 | |
| SCHEMBL4510082 | 0.90 | P2RX7 (0.82) | P2RX7P2RX3 | |
| SCHEMBL4508275 | 0.90 | P2RX7 (0.82) | P2RX7P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034213-A1 | SYSTEMS AND METHODS FOR TARGETING NAD-BASED PATHWAYS FOR TREATMENT OF CANCER | UNIV HONG KONG (CN) | 2026-02-05 | — | — | US | claimed |
| WO-2025229484-A1 | PURINERGIC P2 RECEPTOR ANTAGONISTS FOR USE IN THE TREATMENT OF CONGENITAL SIDEROBLASTIC ANEMIAS | UNIVERSITÀ DEGLI STUDI DI BARI ALDO MORO (IT) | 2025-11-06 | — | — | WO | claimed |
| EP-4157288-A2 | MODULATORS OF PURINERGIC RECEPTORS AND RELATED IMMUNE CHECKPOINT FOR TREATING ACUTE RESPIRATORY DISTRESS SYNDROM | Institut Gustave-Roussy (FR) | 2023-04-05 | — | — | EP | claimed |
| US-20260034213-A1 | SYSTEMS AND METHODS FOR TARGETING NAD-BASED PATHWAYS FOR TREATMENT OF CANCER | UNIV HONG KONG (CN) | 2026-02-05 | — | — | US | disclosed |
| US-20250367144-A1 | TREATMENT OF HYPERINFLAMMATORY SYNDROME | REMICINE IP B V (NL) | 2025-12-04 | — | — | US | disclosed |
| WO-2025229484-A1 | PURINERGIC P2 RECEPTOR ANTAGONISTS FOR USE IN THE TREATMENT OF CONGENITAL SIDEROBLASTIC ANEMIAS | UNIVERSITÀ DEGLI STUDI DI BARI ALDO MORO (IT) | 2025-11-06 | — | — | WO | disclosed |
| US-12419848-B2 | Treatment of hyperinflammatory syndrome | Remicine IP B.V. (NL) | 2025-09-23 | — | — | US | disclosed |
| EP-4582147-A2 | TREATMENT OF HYPERINFLAMMATORY SYNDROME | Remicine IP B.V. (NL) | 2025-07-09 | — | — | EP | disclosed |
| EP-4125843-B1 | TREATMENT OF HYPERINFLAMMATORY SYNDROME | REMICINE IP B V (NL) | 2025-05-21 | — | — | EP | disclosed |
| US-20250144021-A1 | GEL FORMULATIONS FOR LOCAL DRUG RELEASE | TECHNICAL UNIVERSITY OF DENMARK (DK) | 2025-05-08 | — | — | US | disclosed |
| US-12226527-B2 | Gel formulations for local drug release | TECHNICAL UNIVERSITY OF DENMARK (DK) | 2025-02-18 | — | — | US | disclosed |
| CN-116322702-A | Immunomodulation of myeloid-derived suppressor cell function for cancer treatment | 萨吉治疗公司 | 2023-06-23 | — | — | CN | disclosed |
| US-20230128348-A1 | TREATMENT OF HYPERINFLAMMATORY SYNDROME | Remicine IP B.V. (NL) | 2023-04-27 | — | — | US | disclosed |
| EP-4157288-A2 | MODULATORS OF PURINERGIC RECEPTORS AND RELATED IMMUNE CHECKPOINT FOR TREATING ACUTE RESPIRATORY DISTRESS SYNDROM | Institut Gustave-Roussy (FR) | 2023-04-05 | — | — | EP | disclosed |
| EP-4125843-A1 | TREATMENT OF HYPERINFLAMMATORY SYNDROME | Nomoreitis B.V. (BE) | 2023-02-08 | — | — | EP | disclosed |
| CN-115605194-A | Treatment of excessive inflammatory syndrome | 诺莫雷蒂斯私人有限公司（BE） | 2023-01-13 | — | — | CN | disclosed |
| CN-115501172-A | Gel formulations for topical drug delivery | 丹麦技术大学 | 2022-12-23 | — | — | CN | disclosed |
| US-11510910-B2 | HSP90 targeted conjugates and particles and formulations thereof | TVA (ABC), LLC (US) | 2022-11-29 | — | — | US | disclosed |
| CN-115151271-A | Application of glatiramer acetate in preparation of Abeta 42 toxicity inhibitor and scavenger | 长沙英奈发药业有限公司 | 2022-10-04 | — | — | CN | disclosed |
| WO-2022061812-A1 | USE OF GLATIRAMER ACETATE IN PREPARATION OF Aβ42 TOXICITY INHIBITOR AND SCAVENGER | 长沙英奈发药业有限公司 | 2022-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034213-A1 | SYSTEMS AND METHODS FOR TARGETING NAD-BASED PATHWAYS FOR TREATMENT OF CANCER | NAMPT, NADK, CD274 | P2RX7 44/4885P2RX3 33/4885 |
| US-20250144021-A1 | GEL FORMULATIONS FOR LOCAL DRUG RELEASE | TREH, GALE, SLC2A8 | P2RX7 1330/4885P2RX3 1670/4885 |
| US-12226527-B2 | Gel formulations for local drug release | TREH, GALE, SLC2A8 | P2RX7 1330/4885P2RX3 1670/4885 |
| US-11510910-B2 | HSP90 targeted conjugates and particles and formulations thereof | HSP90AB1, HSP90AA1, HSP90B1 | P2RX7 4130/4885P2RX3 4120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.